| ANAVEX LIFE SCI. DL-,001 |
| USA |
| Gesundheit |
| US0327973006 / A1411S |
| 12X1 (Frankfurt) / AVXL (NASDAQ) |
| FRA:12X1, ETR:12X1, 12X1:GR, NASDAQ:AVXL |
| - |
| https://www.anavex.com/ |
|
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syn..
>Volltext.. |
| 166.5 Mio. EUR |
| 62.13 Mio. EUR |
| - |
| -15.45 Mio. EUR |
| -11.58 Mio. EUR |
| -0.13 EUR |
| - |
| 105.22 Mio. EUR |
| -26.05 Mio. EUR |
| 15.38 |
| - |
| 72.12% |
| - |
| - |
| - |
| - |
| ANAVEX |
| 02.10.26 |
|